---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: References"
description: "Reference list for the formulary evidence report on Inaxaplin (VX-147) in APOL1-mediated kidney disease. 162 cited documents."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: References

<a id="references"></a>

## 5 References

1. [AAPC](https://www.aapc.com/codes/cpt-codes/0355U)
2. [Adebayo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12822060/)
3. [Adebayo et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13743002/)
4. [Afsar et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40038200/)
5. [AJMC (2026)](https://www.ajmc.com/view/real-world-amkd-data-highlight-quick-progression-unmet-needs)
6. [Ames et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266825/)
7. [Arkana Laboratories](https://www.arkanalabs.com/services/apol1/no-cost-to-patient-apol1-testing-patient/)
8. [Bensink et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10831785/)
9. [Bensink et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/41222995/)
10. [Bensink et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42101820/)
11. [Blasio et al. (2024)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.2024502b9s3w~small-molecule-apol1-channel-inhibitor-reduces-proteinuria)
12. [Canetta et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6743723/)
13. [Chadban et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12909312/)
14. [Chen et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4670769/)
15. [Chen et al. (2017a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5570668/)
16. [Chen et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5672963/)
17. [Chen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7855571/)
18. [Chertow et al. (2024)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20241x7qn0bv~amplitude-a-phase-23-adaptive-trial-of-inaxaplin-in)
19. [Chertow et al. (2025a)](https://doi.org/10.1093/ndt/gfaf116.0477)
20. [Chertow et al. (2025b)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20252q319dky~inaxaplin-for-a-broad-population-with-apol1-mediated-kidney)
21. [ClinicalTrials.gov NCT04269031](https://clinicaltrials.gov/study/NCT04269031)
22. [ClinicalTrials.gov NCT04340362](https://clinicaltrials.gov/study/NCT04340362)
23. [ClinicalTrials.gov NCT04340362 results](https://clinicaltrials.gov/study/NCT04340362?tab=results)
24. [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)
25. [ClinicalTrials.gov NCT05324410](https://clinicaltrials.gov/study/NCT05324410)
26. [ClinicalTrials.gov NCT05351047](https://clinicaltrials.gov/study/NCT05351047)
27. [ClinicalTrials.gov NCT05865171](https://clinicaltrials.gov/study/NCT05865171)
28. [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)
29. [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796)
30. [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)
31. [ClinicalTrials.gov NCT06824987](https://clinicaltrials.gov/study/NCT06824987)
32. [ClinicalTrials.gov NCT06830629](https://clinicaltrials.gov/study/NCT06830629)
33. [ClinicalTrials.gov NCT06839833](https://clinicaltrials.gov/study/NCT06839833)
34. [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)
35. [da Silva Francisco et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11403072/)
36. [Daneshpajouhnejad et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8877744/)
37. [Datta et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10904047/)
38. [Dogra et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42709370/)
39. [Doshi et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5875947/)
40. [Doshi et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11127222/)
41. [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)
42. [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)
43. [Elsurer Afsar et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13438459/)
44. [EMA orphan designation EU/3/22/2697 (2022)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2697)
45. [EMA paediatric investigation plan EMEA-003368-PIP01-22 (2023)](https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003368-pip01-22)
46. [EMA qualification opinion for GFR slope (2023)](https://www.ema.europa.eu/en/documents/other/qualification-opinion-gfr-slope-validated-surrogate-endpoint-rct-ckd_en.pdf)
47. [EU Clinical Trials Information System 2024-515633-15-00](https://euclinicaltrials.eu/ctis-public/view/2024-515633-15-00)
48. [Falk et al. (2022)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20223311s1181c~design-of-a-phase-23-adaptive-trial-evaluating-inaxaplin-in)
49. [FDA FILSPARI prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216403s006lbl.pdf)
50. [Fierce Biotech (2026)](https://www.fiercebiotech.com/biotech/vertexs-midstage-data-amplify-kidney-disease-market-opportunity)
51. [Foster et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3752955/)
52. [Freedman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4002759/)
53. [Freedman et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4684443/)
54. [Freedman et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6200346/)
55. [Freedman et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7056919/)
56. [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)
57. [Freedman et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41577386/)
58. [Friedman and Pollak (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7863644/)
59. [Gbadegesin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10461697/)
60. [Gbadegesin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11735277/)
61. [Genovese et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2980843/)
62. [Gilbertson et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30454885/)
63. [GlobalData via Pharmaceutical Technology (2024)](https://www.pharmaceutical-technology.com/data-insights/inaxaplin-vertex-pharmaceuticals-net-present-value-3)
64. [Goldschmidt et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11642916/)
65. [Gordon et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6252162/)
66. [Grams et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5004654/)
67. [Grams et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6779370/)
68. [Greensmith et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11473833/)
69. [Gudsoorkar et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31940609/)
70. [Gupta et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10689833/)
71. [Gutiérrez et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6339526/)
72. [Heerspink et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30635226/)
73. [Heerspink et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10278784/)
74. [Heerspink et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41198855/)
75. [Hirth et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13094777/)
76. [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)
77. [Hopper et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42480070/)
78. [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)
79. [Hsu et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42329639/)
80. [Hung et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10631602/)
81. [Inker et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13037386/)
82. [Juliar et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11216883/)
83. [Kalantar-Zadeh et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8484118/)
84. [Kanji et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3231784/)
85. [KDIGO (2021)](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Glomerular-Diseases-Guideline-2021-English.pdf)
86. [KDIGO (2024)](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf)
87. [Kopp et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3231787/)
88. [Kopp et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4446865/)
89. [Krissberg et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8553235/)
90. [Ku et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5237400/)
91. [Kudose et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8806099/)
92. [Labcorp](https://www.labcorp.com/tests/407154/apol1-genotyping)
93. [Levey et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31473020/)
94. [Li et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13190321/)
95. [Li et al. (2026b)](https://doi.org/10.1681/ASN.2026jtffd5vb)
96. [Limb et al. (2024)](https://doi.org/10.1681/ASN.2024mr2v3twq)
97. [Mamak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13278290/)
98. [Mariani et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014854/)
99. [Martinelli et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12980251/)
100. [Maze Therapeutics press release, MZE829 phase 2 topline data (2026)](https://mazetx.gcs-web.com/news-releases/news-release-details/maze-therapeutics-announces-positive-topline-data-phase-2)
101. [Maze Therapeutics third quarter 2026 results (2026)](https://mazetx.gcs-web.com/news-releases/news-release-details/maze-therapeutics-reports-third-quarter-2026-financial-results)
102. [McIntosh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11020447/)
103. [Mohan et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6756958/)
104. [Nadkarni et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5479565/)
105. [Nadkarni et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6482949/)
106. [Nadkarni et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8897752/)
107. [Natera](https://www.natera.com/info/vertex-sponsored-page-program-overview/how-to-order/)
108. [NCQA](https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/measures-list/kidney-health-evaluation-for-patients-with-diabetes-ked/)
109. [Neuen et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42246414/)
110. [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)
111. [Parsa et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3969022/)
112. [Peralta et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4769203/)
113. [Porter et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4934840/)
114. [Rao et al. (2025)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.2025kkecj205~inaxaplin-vx-147-mitigates-apol1-mediated-preeclampsia)
115. [Reeves-Daniel et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3083491/)
116. [Reidy et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6128247/)
117. [Rheault et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37921461/)
118. [Rodrigue et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26845630/)
119. [Roy et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11184510/)
120. [Sadeghi-Alavijeh et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40967557/)
121. [Soler et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37379147/)
122. [Srinivasan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361766/)
123. [Swanepoel et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5983378/)
124. [Szklarzewicz et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12182477/)
125. [Thompson et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6419287/)
126. [Tin et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4974891/)
127. [Travere Therapeutics press release, FILSPARI FSGS approval (2026)](https://www.businesswire.com/news/home/20260413839195/en/)
128. [Troost et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5967666/)
129. [Troost et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854818/)
130. [USRDS Annual Data Report, CKD expenditures (2025)](https://usrds-adr.niddk.nih.gov/2025/chronic-kidney-disease/6-healthcare-expenditures-for-persons-with-ckd)
131. [USRDS Annual Data Report, ESKD incidence and prevalence (2025)](https://usrds-adr.niddk.nih.gov/2025/end-stage-renal-disease/1-incidence-and-prevalence)
132. [USRDS Annual Data Report, ESRD expenditures (2025)](https://usrds-adr.niddk.nih.gov/2025/end-stage-renal-disease/9-healthcare-expenditures-for-persons-with-esrd)
133. [USRDS Annual Data Report, kidney transplant (2025)](https://usrds-adr.niddk.nih.gov/2025/end-stage-renal-disease/7-kidney-transplant)
134. [Vertex Pharmaceuticals earnings call transcript (2026)](https://www.webull.com/news/15858478693325824)
135. [Vertex Pharmaceuticals first quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000171/ex-991_q12026.htm)
136. [Vertex Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm)
137. [Vertex Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/vrtx-20260930.htm)
138. [Vertex Pharmaceuticals press release, AMKD awareness partnership (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-partnership-basketball-hall-famer-alonzo)
139. [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)
140. [Vertex Pharmaceuticals press release, ASN Kidney Week (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-provides-updates-multiple-kidney-programs-american)
141. [Vertex Pharmaceuticals press release, Breakthrough Therapy and PRIME designations (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-inaxaplin-vx-147-granted-breakthrough-therapy)
142. [Vertex Pharmaceuticals press release, kidney portfolio advancements (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-key-advancements-across-kidney-portfolio)
143. [Vertex Pharmaceuticals press release, NEJM publication (2023)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-publication-new-england-journal-medicine)
144. [Vertex Pharmaceuticals press release, phase 2 results (2021)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2-study-vx-147-apol1)
145. [Vertex Pharmaceuticals press release, phase 3 advancement (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-inaxaplin-vx-147-phase-3-portion-adaptive-phase)
146. [Vertex Pharmaceuticals press release, pipeline and business updates (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-provides-pipeline-and-business-updates-advance-upcoming)
147. [Vertex Pharmaceuticals press release, pipeline and business updates (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-provides-pipeline-and-business-updates-advance-upcoming-0)
148. [Vertex Pharmaceuticals press release, pipeline and business updates (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-provides-pipeline-and-business-updates-advance-upcoming-1)
149. [Vertex Pharmaceuticals press release, pivotal development (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-vx-147-pivotal-clinical-development-people-apol1)
150. [Vertex Pharmaceuticals second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000256/ex-991_q22026.htm)
151. [Vertex Pharmaceuticals third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)
152. [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)
153. [Vertex Pharmaceuticals VX19-147-101 statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/SAP_001.pdf)
154. [Wheeler et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9395378/)
155. [WHO Drug Information (2021)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl125.pdf)
156. [Williams and Ingelfinger (2023)](https://pubmed.ncbi.nlm.nih.gov/36920762/)
157. [Wu et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7460910/)
158. [Wyld et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3439392/)
159. [Yee et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13065193/)
160. [Young et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8664705/)
161. [Zimmerman et al. (2021)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20213210s1419a~small-molecule-apol1-inhibitors-block-apol1-pore-function)
162. [Zimmerman et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11696124/)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
